SCHEMBL5160857

SCHEMBL5160857

CCN(CC)C(=O)CC(=O)c1cccs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERCC5 P28715 1/20 0.56
▸ FEN1 P39748 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.55
▸ LMNA P02545 4/20 0.55
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 3/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ POLB P06746 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ HPGD P15428 3/20 0.51
▸ GSK3B P49841 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ KIF11 P52732 1/20 0.47
▸ GAA P10253 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ HDAC1 Q13547 2/20 0.46
▸ CES2 O00748 1/20 0.46
▸ CES1 P23141 1/20 0.46
▸ CTNNB1 P35222 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1923026 0.83 ERCC5 (0.59) ERCC5FEN1ALDH1A1LMNANPC1
Hydrochloric Acid SCHEMBL17203994 0.81 ERCC5 (0.57) ERCC5FEN1ALDH1A1LMNANPC1
SCHEMBL711360 0.80 RAB9A (0.75) ERCC5FEN1ALDH1A1LMNANPC1
SCHEMBL6938391 0.79 USP2 (0.69) ALDH1A1LMNANPC1RAB9AMEN1
SCHEMBL6419377 0.77 ERCC5 (0.61) ERCC5FEN1ALDH1A1LMNANPC1
SCHEMBL4963671 0.77 USP2 (0.68) ALDH1A1LMNANPC1RAB9AMEN1
SCHEMBL1547840 0.77 ERCC5 (0.65) ERCC5FEN1ALDH1A1LMNANPC1
SCHEMBL81392 0.77 ALDH1A1 (0.62) ERCC5FEN1ALDH1A1LMNANPC1
SCHEMBL22080098 0.76 ALDH1A1 (0.56) ALDH1A1LMNANPC1RAB9AMEN1
SCHEMBL1232758 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 — — US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 — — EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 — — US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ERCC5 1067/4885FEN1 1305/4885ALDH1A1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback